uzspbgmuУчёные записки Первого Санкт-Петербургского государственного медицинского университета имени академика И. П. ПавловаThe Scientific Notes of the Pavlov University1607-41812541-8807Academician I.P. Pavlov First St. Petersburg State Medical University10.24884/1607-4181-2021-28-4-9-21uzspbgmu-852Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESВысокодозная иммуносупрессивная терапия с аутологичной трансплантацией гемопоэтических стволовых клеток при рассеянном склерозе: современный взгляд на метод (обзор литературы)High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation in multiple sclerosis: a modern view of the method (review of literature)https://orcid.org/0000-0001-8699-2482ПолушинА. Ю.PolushinA. Yu.

Полушин Алексей Юрьевич, кандидат медицинских наук, руководитель отделения химиотерапии и трансплантации костного мозга при онкологических и аутоиммунных заболеваниях, заведующий научно-исследовательской лабораторией нейроонкологии и аутоиммунных заболеваний НИИ детской онкологии, гематологии и трансплантологии им. Р. М. Горбачёвой, доцент кафедры неврологии

197022, Санкт-Петербург, ул. Льва Толстого, д. 6-8

Alexey Yu. Polushin, Cand. of Sci. (Med.), Chief of the Chemotherapy and SCT Unit for Cancer and AID, Head of the Laboratory of Neurooncology and AID of R.M. Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, Associate Professor of the Department of Neurology

6-8, L’va Tolstogo str., Saint Petersburg, 197022

 

alexpolushin@yandex.ruhttps://orcid.org/0000-0002-3881-4486ЗаляловЮ. Р.ZalyalovYu. R.

Залялов Юрий Ринатович, кандидат медицинских наук, зав. блоком химиотерапии и трансплантации костного мозга при онкологических и аутоиммунных заболеваниях

Санкт-Петербург

Yuri R. Zalyalov, Cand. of Sci. (Med.), Head of the Chemotherapy and SCT Unit for Cancer and AID

Saint Petersburg

yz21@mail.ruhttps://orcid.org/0000-0002-6715-8203ТотолянН. А.TotolyanN. A.

Тотолян Наталья Агафоновна, доктор медицинских наук, профессор кафедры неврологии

Санкт-Петербург

Natalia A. Totolyan, Dr. of Sci. (Med.), Professor of the Department of Neurology

Saint Petersburg

ntotolyan@mail.ruhttps://orcid.org/0000-0002-9589-4136КулагинА. Д.KulaginA. D.

Кулагин Александр Дмитриевич, доктор медицинских наук, доцент, директор НИИ детской онкологии, гематологии и трансплантологии им. Р. М. Горбачёвой, заведующий кафедрой гематологии, трансфузиологии и трансплантологии с курсом детской онкологии ФПО им. профессора Б. В. Афанасьева

Санкт-Петербург

Alexander D. Kulagin, Dr. of Sci. (Med.), Associate Professor, Director, R.M. Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, Head, Professor, B. V. Afanasyev Department of Hematology, Transfusion Medicine and Transplantation with the Course of Pediatric Oncology

Saint Petersburg

kulagingem@rambler.ruhttps://orcid.org/0000-0002-5884-3110СкоромецА. А.SkorometsA. A.

Alexander A. Skoromets, Academician of the Russian Academy of Sciences, Dr. of Sci. (Med.), Professor, Hear of the Department of Neurology

Saint Petersburg

askoromets@gmail.comФедеральное государственное бюджетное образовательное учреждение высшего образования «Первый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова» Министерства здравоохранения Российской ФедерацииРоссияPavlov UniversityRussian Federation202119012022284921Copyright © Полушин А.Ю., Залялов Ю.Р., Тотолян Н.А., Кулагин А.Д., Скоромец А.А., 20222022Полушин А.Ю., Залялов Ю.Р., Тотолян Н.А., Кулагин А.Д., Скоромец А.А.Polushin A.Y., Zalyalov Y.R., Totolyan N.A., Kulagin A.D., Skoromets A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sci-notes.ru/jour/article/view/852

В мире отмечается рост заболеваемости рассеянным склерозом. Лишь в половине случаев стандартная терапия позволяет на непродолжительное время добиваться контроля над этим заболеванием. Высокодозная иммуносупрессивная терапия с аутологичной трансплантацией гемопоэтических стволовых клеток является перспективным и эффективным методом лечения аутоиммунных заболеваний, в том числе рассеянного склероза. За последние 20 лет достигнут прогресс в понимании иммунных механизмов метода. Значимо уменьшена частота и выраженность нежелательных явлений терапии за счет снижения интенсивности режимов кондиционирования. Целью настоящего обзора является анализ научных публикаций, посвященных эффективности метода, данных по выбору оптимальных условий и критериев его применения при рассеянном склерозе.

There is an increase in the incidence of multiple sclerosis in the world. Only in half of the cases, standard therapy allows for a short time to achieve control over this disease. High-dose immunosuppressive therapy and autologous hematopoietic stem cells transplantation is a promising and effective method of treating autoimmune diseases, including multiple sclerovsis. Over the past 20 years, progress has been made in understanding the immune mechanisms of the method. At present, the frequency and severity of adverse events of therapy significantly decreased by reducing the intensity of conditioning regimens. The objective of this review was to analyze scientific publications on the effectiveness of the method, and the data on the optimal conditions and criteria for its use in multiple sclerosis.

 

клиническая апробациявысокодозная иммуносупрессивная терапиярассеянный склерозгемопоэтические стволовые клеткитрансплантацияиммунотерапияаферезмобилизацияclinical approbationhigh-dose immunosuppressive therapymultiple sclerosishematopoietic stem cellstransplantationimmunotherapyapheresismobilizationReferencesSumelahti M. L., Tienari P. J., Wikstrom J. et al. Regional and temporal variation in the incidence of multiple sclerosis in Finland 1979–1993 // Neuroepidemiology. – 2000. – Vol. 19. – P. 67–75. Doi: 10.1159/000026241Sumelahti M. L., Tienari P. J., Wikstrom J., Palo J., Hakama M. Regional and temporal variation in the incidence of multiple sclerosis in Finland 1979–1993 // Neuroepidemiology. 2000;(19):67–75. Doi: 10.1159/000026241.Incidence of multiple sclerosis in the United Kingdom: findings from a population-based cohort / A. Alonso, S. S. Jick, M. J. Olek, M. A. Hernan // J. Neurol. – 2007. – Vol. 254. – P. 1736–1741. Doi: 10.1007/s00415-007-0602-z.Alonso A., Jick S. S., Olek M. J., Hernan M. A. Incidence of multiple sclerosis in the United Kingdom: findings from a population-based cohort. J Neurol 2007;(254):1736– 1741. Doi: 10.1007/s00415-007-0602-z.Fromont A., Binquet C., Sauleau E. et al. National estimate of multiple sclerosis incidence in France (2001–2007). Mult Scler. – 2012. – Vol. 18, № 8. – P. 1108–1115. Doi: 10.1177/1352458511433305.Fromont A., Binquet C., Sauleau E., Fournel I., Despalins R. et al. National estimate of multiple sclerosis incidence in France (2001–2007). Mult Scler. 2012;(8):1108–1115. Doi: 10.1177/1352458511433305.Laureys G., Willekens B., Vanopdenbosch L. et al. A Belgian Consensus Protocol for Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis // Acta Neurol Belg. – 2018. – Vol. 118, № 2. – P. 161–168. Doi: 10.1007/s13760-018-0905-0.Laureys G., Willekens B., Vanopdenbosch L., Deryck O. et al. A Belgian Consensus Protocol for Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. Acta Neurol Belg. 2018;118(2):161–168. Doi: 10.1007/s13760-018-0905-0.Autologous haematopoietic stem cell transplantation for neurological diseases / J. Burman, A. Tolf, H. Hоgglund, H. Askmark // J. Neurol. Neurosurg. Psychiatry. – 2018. – Vol. 89, № 2. – P. 147–155. Doi: 10.1136/jnnp-2017-316271.Burman J., Tolf A., Hоgglund H., Askmark H. Autologous haematopoietic stem cell transplantation for neurological diseases // J Neurol Neurosurg Psychiatry. 2018;89(2):147– 155. Doi: 10.1136/jnnp-2017-316271.Сизикова С. А., Лисуков И. А., Кулагин А. Д. и др. Высокодозная иммуносупрессивная терапия с аутологичной трансплантацией стволовых кроветворных клеток при аутоиммунных заболеваниях // Терапевт. арх. – 2002. – Т. 74, № 7. – С. 22–26.Sizikova S. A., Lisukov I. A., Kulagin A. D., Kryuchkova I. V., Gilevich A. V., Chernykh E. R., Leplina O. Yu., Konenkova L. P., Zonova E. V., Shirinsky V. S., Sentyakova T. N., Demin A. A., Kozlov V. A. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation in autoimmune diseases // Therapeutic Archive. 2002;74(7):22–26. (In Russ.).Шевченко Ю. Л., Новик А. А., Кузнецов А. Н. и др. Аутологичная трансплантация кроветворных стволовых клеток при рассеянном склерозе: результаты исследования российской кооперативной группы клеточной терапии // Невролог. журн. – 2008. – Т. 13, № 2. – С. 11–18.Shevchenko Y. L., Novik A. A., Kuznetsov A. N., Afanasyev B. V., Lisukov I. A., Kozlov V. A., Myasnikov A. A., Rukavitsyn O. A., Ionova T. I., Melnichenko V. Ya., Fedorenko D. A., Baziy N. I., Shamansky S. V., Kulagin A. D., Kishtovich A. V., Ivanov P. A., Gorodokin G. Autologous transplantation of hematopoietic stem cells in multiple sclerosis: results of a study of the Russian cooperative cell therapy group. Neurological Journal. 2008;13(2):11–18. (In Russ.).Приказ Министерства здравоохранения РФ от 10 июля 2015 г. № 433н. «Об утверждении Положения об организации клинической апробации методов профилактики, диагностики, лечения и реабилитации и оказания медицинской помощи в рамках клинической апробации методов профилактики, диагностики, лечения и реабилитации (в том числе порядка направления пациентов для оказания такой медицинской помощи), типовой формы протокола клинической апробации методов профилактики, диагностики, лечения и реабилитации». URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/028/360/original/Приказ_№433н_от_10_июля_2015_г..pdf?1447421228 (дата обращения: 10.12.2021).Order of the Ministry of Health of the Russian Federation No. 433n. July 10, 2015. «On approval of the Regulations on the organization of clinical testing of methods of prevention, diagnosis, treatment and rehabilitation and medical care within the framework of clinical testing of methods of prevention, diagnosis, treatment and rehabilitation (including the procedure for referral of patients for such medical care), the standard form of the protocol of clinical testing of methods of prevention, diagnosis, treatment and rehabilitation». Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/028/360/original/Приказ_№433н_от_10_июля_2015_г..pdf?1447421228 (accessed: 10.12.2021).Приказ Министерства здравоохранения РФ от 21 июля 2015 г. № 474н. «О порядке дачи информированного добровольного согласия на оказание медицинской помощи в рамках клинической апробации методов профилактики, диагностики, лечения и реабилитации, формах информированного добровольного согласия на оказание медицинской помощи в рамках клинической апробации методов профилактики, диагностики, лечения и реабилитации и отказа от медицинской помощи в рамках клинической апробации методов профилактики, диагностики, лечения и реабилитации». URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/028/351/original/Приказ_№474н_от21июля_2015_г..pdf?1447419558 (дата обращения: 10.12.2021).Order of the Ministry of Health of the Russian Federation No. 474n July 21, 2015. «On the procedure for giving informed voluntary consent to the provision of medical care within the framework of clinical testing of methods of prevention, diagnosis, treatment and rehabilitation, forms of informed voluntary consent to the provision of medical care within the framework of clinical testing of methods of prevention, diagnosis, treatment and rehabilitation and refusal of medical care within the framework of clinical testing of methods of prevention, diagnosis, treatment and rehabilitation». Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/028/351/original/Приказ_№474н_от21июля_2015_г..pdf?1447419558 (accessed: 10.12.2021).Currò D., Mancardi G. Autologous hematopoietic stem cell transplantation in multiple sclerosis: 20 years of experience // Neurol Sci. – 2016. – Vol. 37, № 6. – P. 857–865. Doi: 10.1007/ s10072-016-2564-3. Epub 2016 Apr 12.PMID: 27071689.Currò D., Mancardi G. Autologous hematopoietic stem cell transplantation in multiple sclerosis: 20 years of experience // Neurol Sci. 2016;37(6):857–865. Doi: 10.1007/s10072-016-2564-3. Epub 2016 Apr 12.PMID: 27071689.Moore J., Brooks P., Milliken S. et al. A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis // Arthritis Rheum. – 2002. – Vol. 46, № 9. – P. 2301–2309. Doi: 10.1002/art.10495.Moore J., Brooks P., Milliken S., Biggs J., Ma D., Handel M. et al. A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. Arthritis Rheum. 2002;46(9):2301–2309. Doi: 10.1002/art.10495.Atkins H. L., Bowman M., Allan D. et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial // Lancet. – Vol. 2016, № 388. – P. 576–585. Doi: 10.1016/S0140-6736(16)30169-6.Atkins H. L., Bowman M., Allan D. et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial // Lancet 2016;(388):576–585. Doi: 10.1016/S0140-6736(16)30169-6.Feng X. et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro // Blood. – 2008. – Vol. 111. – P. 3675–3683. Doi: 10.1182/blood-2008-01-130146.Feng X. et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood. 2008;(111):3675–3683. Doi: 10.1182/blood-2008-01-130146.Karussis D. M., Slavin S., Lehmann D. et al. Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation // J. Immunol. – 1992. – Vol. 148. – P. 1693–1698.Karussis D. M., Slavin S., Lehmann D. et al. Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation // J Immunol. 1992;(148):1693–1698.Karussis D. M., Vourka-Karussis U., Lehmann D. et al. Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation // J. Clin. Invest. – Vol. 1993, № 92. – P. 765–772.Karussis D. M., Vourka-Karussis U., Lehmann D. et al. Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation // J Clin Invest 1993; (92):765–772.Van Gelder M., Kinwel-Bohré E. P., van Bekkum D. W. Treatment of experimental allergic encephalomyelitis in rats with total body irradiation and syngeneic BMT // Bone Marrow Transplant. – 1993. – Vol. 11. – P. 233–241.Van Gelder M., Kinwel-Bohré E. P., van Bekkum D. W. Treatment of experimental allergic encephalomyelitis in rats with total body irradiation and syngeneic BMT // Bone Marrow Transplant. 1993;(11):233–241.Darlington P. J., Touil T., Doucet J. S. et al. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation // Ann Neurol. – Vol. 2013, № 73. – P. 341–354. Doi: 10.1002/ana.23784.Darlington P. J., Touil T., Doucet J. S. et al. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation // Ann Neurol 2013;(73):341–354. Doi: 10.1002/ana.23784.Karnell F. G., Lin D., Motley S. et al. Reconstitution of immune cell populations in multiple sclerosis patients after autologous stem cell transplantation // Clin. Exp. Immunol. – 2017. – Vol. 189, № 3. – P. 268–278. Doi: 10.1111/cei.12985.Karnell F. G., Lin D., Motley S., Duhen T., Lim N., Campbell D. J., Turka L. A., Maecker H. T., Harris K. M. Reconstitution of immune cell populations in multiple sclerosis patients after autologous stem cell transplantation // Clin Exp Immunol. 2017;189(3):268–278. Doi: 10.1111/cei.12985.Regenerating Immunotolerance in Multiple Sclerosis with Autologous Hematopoietic Stem Cell Transplant / J. C. Massey, I. J. Sutton, D. D. F. Ma, J. J. Moore // Front Immunol. – 2018. –12, № 9. – P. 410. Doi: 10.3389/fimmu.2018.00410.Massey J. C., Sutton I. J., Ma D. D. F., Moore J. J. Regenerating Immunotolerance in Multiple Sclerosis with Autologous Hematopoietic Stem Cell Transplant // Front Immunol. 2018;12(9):410. Doi: 10.3389/fimmu.2018.00410.Meng L., Ouyang J., Zhang H. et al. Treatment of an autoimmune encephalomyelitis mouse model with nonmyeloablative conditioning and syngeneic bone marrow transplantation // Restor Neurol. Neurosci. – 2011. – Vol. 29. – P. 177–185. Doi: 10.3233/RNN-2011-0590.Meng L., Ouyang J., Zhang H., Wen Y., Chen J., Zhou J. Treatment of an autoimmune encephalomyelitis mouse model with nonmyeloablative conditioning and syngeneic bone marrow transplantation // Restor Neurol Neurosci 2011;(29):177–185. Doi: 10.3233/RNN-2011-0590.Abrahamsson S. V., Angelini D. F., Dubinsky A. N. et al. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis // Brain. – 2013. – Vol. 136. – P. 2888–2903. Doi: 10.1093/brain/awt182.Abrahamsson S. V., Angelini D. F., Dubinsky A. N. et al. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis // Brain 2013;(136):2888–2903. Doi: 10.1093/brain/awt182.Arruda L. C., Lorenzi J. C., Sousa A. P. et al. Autologous hematopoietic SCT normalizes miR-16, -155 and -142- 3p expression in multiple sclerosis patients // Bone Marrow Transplant. – 2015. – Vol. 50. – P. 380–389. Doi: 10.1038/bmt.2014.277.Arruda L. C., Lorenzi J. C., Sousa A. P. et al. Autologous hematopoietic SCT normalizes miR-16, -155 and -142- 3p expression in multiple sclerosis patients // Bone Marrow Transplant. 2015;(50): 380–389. Doi: 10.1038/bmt.2014.277.Mancardi G., Sormani M., Muraro P. et al. Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis. Mult Scler. – 2018. – Vol. 24, № 3. – P. 245–255. Doi: 10.1177/1352458517742532.Mancardi G., Sormani M., Muraro P., Boffa G., Saccardi R. Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis // Mult Scler. 2018;24(3):245–255. Doi: 10.1177/1352458517742532.Snowden J., Sharrack B., Akil M. et al. Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases – a guide for the generalist // Clin Med (Lond). – 2018. – Vol. 18, № 4. – P. 329–334. Doi: 10.7861/clinmedicine.18-4-329Snowden J., Sharrack B., Akil M., Kiely D., Lobo A., Kazmi M., Muraro P., Lindsay J. Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases – a guide for the generalist // Clin Med (Lond). 2018;18(4):329–334. Doi: 10.7861/clinmedicine.18-4-329.Sharrack B., Saccardi R., Alexander T. et al. European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and EBMT (JACIE). Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE) // Bone Marrow Transplant. –2020. – Vol. 55, № 2. – P. 283–306. Doi: 10.1038/s41409-019-0684-0.Sharrack B., Saccardi R., Alexander T., Badoglio M., Burman J., Farge D., Greco R., Jessop H., Kazmi M., Kirgizov K., Labopin M., Mancardi G., Martin R., Moore J., Muraro P. A., Rovira M., Sormani M. P., Snowden J. A. European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and EBMT (JACIE). Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE) // Bone Marrow Transplant. 2020;55(2):283–306. Doi: 10.1038/s41409-019-0684-0.Nash R. A., Hutton G. J., Racke M. K. et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsingremitting multiple sclerosis (HALT-MS): A 3-year interim report // JAMA Neurol. – 2015. – Vol. 72. – P. 159–169. Doi: 10.1001/jamaneurol.2014.3780.Nash R. A., Hutton G. J., Racke M. K. et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsingremitting multiple sclerosis (HALT-MS): A 3-year interim report // JAMA Neurol 2015;(72):159–169. Doi: 10.1001/jamaneurol.2014.3780.Mancardi G. L., Sormani M. P., Gualandi F. et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial // Neurology. – 2015. – Vol. 84. – P. 981–988. Doi: 10.1212/WNL.0000000000001329.Mancardi G. L., Sormani M. P., Gualandi F. et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial // Neurology. 2015;(84):981–988. Doi: 10.1212/WNL.0000000000001329.Muraro P. A., Pasquini M., Atkins H. L. et al. Longterm outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis // JAMA Neurol. – 2017. – Vol. 74. – P.459–469. Doi: 10.1001/jamaneurol.2016.5867.Muraro P. A., Pasquini M., Atkins H. L. et al. Longterm outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis // JAMA Neurol 2017;(74):459–469. Doi: 10.1001/jamaneurol.2016.5867.Burman J., Iacobaeus E., Svenningsson A. et al. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. J Neurol Neurosurg Psychiatry. – 2014. – Vol. 85. – P. 1116–1121. Doi: 10.1136/jnnp-2013-307207.Burman J., Iacobaeus E., Svenningsson A. et al. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience // J Neurol Neurosurg Psychiatry. 2014;(85):1116–1121. Doi: 10.1136/jnnp-2013-307207.Nash R. A. et al. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS // Neurology. – 2017. – Vol. 88. – P. 842–852. Doi: 10.1212/WNL.0000000000003660.Nash R. A. et al. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS // Neurology. 2017;(88):842–852. Doi: 10.1212/WNL.0000000000003660.Jones J. L., Coles A. J. Mode of action and clinical studies with alemtuzumab // Exp Neurol. – 2014. – Vol. 262. – P. 37–43. Doi: 10.1016/j.expneurol.2014.04.018.Jones J. L., Coles A. J. Mode of action and clinical studies with alemtuzumab. Exp Neurol. 2014 ;(262):37–43. Doi: 10.1016/j.expneurol.2014.04.018.Gelfand J. M., Cree B. A. C., Hauser S. L. Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis // Neurotherapeutics. – 2017. – Vol. 14, № 4. – P. 835–841. Doi: 10.1007/s13311-017-0557-4.Gelfand J. M., Cree B. A. C., Hauser S. L. Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis // Neurotherapeutics. 2017;14(4):835–841. Doi: 10.1007/s13311-017-0557-4.Sormani M. P., Muraro P. A., Saccardi R. et al. NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs // Mult Scler. – 2017. – Vol. 23. – P. 201–204. Doi: 10.1177/1352458516645670.Sormani M. P., Muraro P. A., Saccardi R. et al. NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs // Mult Scler. 2017;(23):201–204. Doi: 10.1177/1352458516645670.Polman C. H., O’Connor P. W., Havrdova E. et al. AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis // N Engl J Med. 2006;354(9):899–910. Doi: 10.1056/NEJMoa044397.Polman C. H., O’Connor P. W., Havrdova E., Hutchinson M., Kappos L., Miller D. H., Phillips J. T., Lublin F. D., Giovannoni G., Wajgt A., Toal M., Lynn F., Panzara M. A., Sandrock A. W. AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis // N Engl J Med. 2006;354(9):899–910. Doi: 10.1056/NEJMoa044397.Burt R. K. et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study // Lancet Neurol. – 2009. – Vol. 8. – P. 244–253.Burt R. K. et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study // Lancet Neurol. 2009; (8):244–253.Giovannoni G., Comi G., Cook S. et al. CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis // N Engl J Med. – 2010. – Vol. 362, № 5. – P. 416–426. Doi: 10.1056/NEJMoa0902533.Giovannoni G., Comi G., Cook S., Rammohan K., Rieckmann P., Soelberg Sørensen P., Vermersch P., Chang P., Hamlett A., Musch B., Greenberg S. J. CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis // N Engl J Med. 2010;362(5):416–426. Doi: 10.1056/NEJMoa0902533.Hamerschlak N. et al. Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/ horse ATG and CY/rabbit ATG // Bone Marrow Transplant. – 2010. – Vol. 45. – P. 239–248. Doi: 10.1038/bmt.2009.127.Hamerschlak N. et al. Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG // Bone Marrow Transplant. 2010;(45):239–248. Doi: 10.1038/bmt.2009.127.Long term benefit of multiple sclerosis treatment: an investigation using a novel data collection technique / D. S. Conway, D. M. Miller, R. G. O’Brien, J. A. Cohen // Mult Scler. –2012. – Vol. 18, № 11. – P.1617–1624. Doi: 10.1177/1352458512449681.Conway D. S., Miller D. M., O’Brien R. G., Cohen J. A. Long term benefit of multiple sclerosis treatment: an investigation using a novel data collection technique // Mult Scler. 2012;18(11):1617–1624. Doi: 10.1177/1352458512449681.Gold R., Kappos L., Arnold D. L. et al. DEFINE Study Investigators // N Engl J Med. –2012. – Vol. 367, № 12. – P. 1098–107. Doi: 10.1056/NEJMoa1114287.Gold R., Kappos L., Arnold D. L., Bar-Or A., Giovannoni G., Selmaj K., Tornatore C., Sweetser M. T., Yang M., Sheikh S. I., Dawson K. T. DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis // N Engl J Med. 2012;367(12):1098–1107. Doi: 10.1056/NEJMoa1114287.Kappos L., O’Connor P., Radue E. W. et al. Longterm effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial // Neurology. – 2015– Vol. 8, № 15. – P. 1582–1591. Doi: 10.1212/WNL.0000000000001462.Kappos L., O’Connor P., Radue E. W., Polman C., Hohlfeld R., Selmaj K., Ritter S., Schlosshauer R., von Rosenstiel P., Zhang-Auberson L., Francis G. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial // Neurology. 2015;84(15):1582–1591. Doi: 10.1212/WNL.0000000000001462.Reston J. T., Uhl S., Treadwell J. R. et al. Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review // Mult. Scler. – 2011. – Vol. 17. – P. 204–213.Reston J. T., Uhl S., Treadwell J. R., Nash R. A., Schoelles K. Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review // Mult. Scler. 2011; (17):204–213.Burt R. K., Balabanov R., Burman J. et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis // JAMA. – 2019. – Vol. 321, № 2. – P. 165–174. Doi: 10.1001/jama.2018.18743.Burt R. K., Balabanov R., Burman J. et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis // JAMA. 2019;321(2):165–174. Doi: 10.1001/jama.2018.18743Fassas A. On the evolution of high-dose immunosuppressive therapy with autologous stem cell transplantation in multiple sclerosis // Cell Ther Transplant. – 2010. – Vol. 2. – P. E000060.01. Doi: 10.3205/ctt-2010-en-000060.01.Fassas A. On the evolution of high-dose immunosuppressive therapy with autologous stem cell transplantation in multiple sclerosis // Cell Ther Transplant. 2010;(2):E000060.01. Doi: 10.3205/ctt-2010-en000060.01.Saccardi R. et al. for the Italian GITMO-Neuro Intergroup: Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. – 2005. – Vol. 105, № 6. – P. 2601–2607. Doi: 10.1182/blood-2004-08-3205.Saccardi R. et al. for the Italian GITMO-Neuro Intergroup: Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. 2005;105(6):2601–2607. Doi: 10.1182/blood-2004-08-3205.Полушин А. Ю., Залялов Ю. Р., Винокурова А. Н. и др. Эффективность высокодозной иммуносупрессивной терапии с последующей аутологичной трансплантацией гемопоэтических стволовых клеток при прогрессирующих типах рассеянного склероза: опыт НИИ ДОГиТ им. Р. М. Горбачевой // Гематология и трансфузиология. – 2020. – Т. 65, № 1. – C. 202.Polushin A. Yu., Zalyalov Yu. R., Vinokurova A. N., Skiba Ya. B., Estrina M. A., Kulagin A. D., Vereshchagina I. V., Totolyan N. A., Skoromets A. A., Afanasyev B. V. Effectiveness of high-dose immunosuppressive therapy with subsequent autologous hematopoietic stem cell transplantation in progressive types of multiple sclerosis: the experience of the R.M. Gorbacheva Research Institute of DOGiT. Hematology and Transfusiology // Russian journal of hematology and transfusiology (gematologiya i transfusiologiya). 2020; 65(1):202. (In Russ.).Fassas A., Kimiskidis V. K., Sakellari I. et al. Longterm results of stem cell transplantation for MS: A single center experience // Neurology. – 2011. – Vol. 76, № 12. – P. 1066–1070. Doi: 10.1212/WNL.0b013e318211c537.Fassas A., Kimiskidis V. K., Sakellari I. et al. Longterm results of stem cell transplantation for MS: A single center experience // Neurology. 2011;76(12):1066–1070. Doi: 10.1212/WNL.0b013e318211c537.Cull G. et al. Lymphocyte reconstitution following autologous stem cell transplantation for progressive MS // Mult Scler J Exp Transl Clin. – 2017– Vol. 3, № 1. – P. 2055217317700167. Doi: 10.1177/2055217317700167.Cull G. et al. Lymphocyte reconstitution following autologous stem cell transplantation for progressive MS // Mult Scler J Exp Transl Clin. 2017;3(1):2055217317700167. Doi: 10.1177/2055217317700167.Киргизов К. И., Скоробогатова Е. В., Бембеева Р. Ц. и др. Аутологичная трансплантация гемопоэтических стволовых клеток у детей с тяжелыми рефрактерными формами рассеянного склероза // Вопросы современной педиатрии. – 2013. – Т. 12, № 1. –С. 149–152. Doi: 10.15690/vsp.v12i1.572.Kirgizov K. I., Skorobogatova E. V., Bembeeva R. Ts., Volkova E. Yu., Bologov A. A., Pilia S. V., Maschan A. A., Rumyantsev A. G. Autologous hematopoietic stem cell transplantation in children with severe refractory forms of multiple sclerosis // Issues of modern pediatrics. 2013;12(1):149–152. (In Russ.). Doi: Doi.org/10.15690/vsp.v12i1.572.Gratwohl A., Passweg J., Bocelli-Tyndall C. et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplantation. – 2005. – Vol. 35, № 9. – P. 869–879. Doi: 10.1038/sj.bmt.1704892.Gratwohl A., Passweg J., Bocelli-Tyndall C., Fassas A. et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases // Bone Marrow Transplantation. 2005;35(9):869–79. Doi: 10.1038/sj.bmt.1704892.Arruda L. C. M., de Azevedo J. T. C., de Oliveira G. L. V. et al. Immunological correlates of favorable long-term clinical outcome in multiple sclerosis patients after autologous hematopoietic stem cell transplantation // Clin. Immunol. – 2016. – Vol. 169. – P. 47–57. Doi: 10.1016/j.clim.2016.06.005.Arruda L. C. M., de Azevedo J. T. C., de Oliveira G. L. V., Scortegagna G. T., Rodrigues E. S., Palma P. V. B. et al. Immunological correlates of favorable long-term clinical outcome in multiple sclerosis patients after autologous hematopoietic stem cell transplantation // Clin Immunol 2016; (169):47–57. Doi: 10.1016/j.clim.2016.06.005.Comi G. et al. Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation // J. Neurol. – 2000. – Vol. 247. – P. 376–382. Doi: 10.1007/s004150050605.Comi G. et al. Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation // J. Neurol. 2000;(247):376–382. Doi: 10.1007/s004150050605.Afanasyev B. V. et al. Indications for hematopoietic stem cell transplantation. 2nd Edition // Based on EBMT Recommendations of Cellular Therapy and Transplantation. – 2019. – Vol. 4, № 8. – P. 101–145. Doi: 10.18620/ctt-1866-8836-2019-8-4-101-145.Afanasyev B. V. et al. Indications for hematopoietic stem cell transplantation. 2nd ed. // Based on EBMT Recommendations of Cellular Therapy and Transplantation. 2019; 8(4):101–145. Doi: 10.18620/ctt-1866-8836-2019-8-4-101-145Duarte R. F. et al. Indications for haematopoiet¬ic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe // Bone Marrow Trans-plant. – 2019. – Vol. 54, № 10. – P. 1525– 1552. Doi:10.1038/s41409-019-0516-2Duarte R. F. et al. Indications for haematopoiet¬ic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe // Bone Marrow Trans-plant. 2019;54(10):1525–1552. Doi: 10.1038/s41409-019-0516-2.Cohen J. A., Baldassari L. E., Atkins H. L. et al. Autologous hematopoietic cell transplantation for treatment-refractory relapsing multiple sclerosis: position statement from the American Society for Blood and Marrow Transplantation // Biol. Blood Marrow Transplant. – 2019. – Vol. 25. – P. 845– 854. Doi: 10.1016/j.bbmt.2019.02.014.Cohen J. A., Baldassari L. E., Atkins H. L., Bowen J. D., Bredeson C., Carpenter P. A. et al. Autologous hematopoietic cell transplantation for treatment-refractory relapsing multiple sclerosis: position statement from the American Society for Blood and Marrow Transplantation // Biol Blood Marrow Transplant. 2019;(25):845–854. Doi: 10.1016/j.bbmt.2019.02.014.

The authors declare that there are no conflicts of interest present.